RE:RE:Could CG have a peek at raw data?Given this and the points raised by mercedesman it's not inconceivable that CG could make an offer for Spectral before the release of Tigris top line data and possibly even before the official CG Vantive takeover in late 2024 or early 2025.
If anyone intends to buy more shares it might be best not to wait much longer.
hmmmmmmmm wrote: If you look back at any of the Spectral's recent corprate updates they state:
"In anticipation of a positive Tigris trial outcome, the Company has been working closely with Baxter on post-approval marketing plans for PMX commercialization. This includes developing product branding, pricing and roll-out plans with numerous Baxter departments, including marketing, regulatory, clinical and reimbursement. Baxter has communicated its intention to undertake a broad marketing campaign on day one of FDA approval for PMX."
As CG /Vantive will be taking on that workload (for the distribution deal) they of course need to know PMX's chances for approval and consequently how much money and resources they want to allocate to it in the immediate term.
So, Yes. The new owners will have every right and need to immediately look at the trial data.
And yes, if they like what they see they are ging to be savages in the box.